Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease
ParkFit
The ParkFit Study; Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease
1 other identifier
interventional
700
1 country
32
Brief Summary
Patients with Parkinson's disease (PD) are heavily inclined towards a sedentary lifestyle. This is caused by a combination of physical impairments and cognitive dysfunction. However, regular physical activity in PD is highly desirable, for two reasons. First, physical activity has positive generic effects in preventing complications such as cardiovascular diseases, type II diabetes mellitus, osteoporosis and certain cases of cancer. Secondly, physical activity has additional disease-specific merits in PD such as depression, sleep disturbances and constipation. These effects lead to raised quality of life. Furthermore, animal studies suggest that physical activity could slow down disease progression. Simply informing patients about the importance of physical activity is not enough to initiate and maintain an adequate level of physical activity. We propose to develop a physical activity promoting program for sedentary patients with PD in order to raise their level of daily physical activity. Objective: The first aim of the study is to investigate whether a physical activity promotion program will result in an increase in physical activity in sedentary patients with PD. The second aim is to demonstrate an increase in physical fitness and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2008
Typical duration for phase_3
32 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2008
CompletedFirst Submitted
Initial submission to the registry
September 5, 2008
CompletedFirst Posted
Study publicly available on registry
September 8, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedJanuary 31, 2012
January 1, 2012
3.2 years
September 5, 2008
January 27, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Level of Physical Activity based on the LAPAQ questionnaire
Average of 6, 12, 18 and 24 months
Secondary Outcomes (13)
One week diary of physical activity
Average of 6, 12, 18 and 24 months
Level of Physical Activity based on an activity monitor
continuous during 24 months
Physical Fitness (Six Minute Walk Test & Astrand bicycle test)
12 and 24 months
Quality of Life (PDQ-39)
6, 12, 18 and 24 months
Mood and Depression (HADS)
6, 12, 18 and 24 months
- +8 more secondary outcomes
Study Arms (2)
A
EXPERIMENTALPhysical Therapy aimed to promote the level of physical activity
B
ACTIVE COMPARATORPhysical Therapy aimed to move safely
Interventions
Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement. Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes
Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
Eligibility Criteria
You may qualify if:
- Idiopathic PD
- Hoehn and Yahr stage I-III
- Between 40 and 75 years old
- Not meeting the norm for healthy physical activity: the latter being defined according to international standards as either five days a week 30 minutes of moderate-intensity physical activity, or 3 days a week 20 minutes of vigorous-intensity physical activity
You may not qualify if:
- Wheel chair bounded
- Severe co-morbidity (e.g. orthopaedic disorders or chronic hart failure)
- Severe cognitive decline, defined as Mini Mental State Examination \< 24
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (32)
Tergooiziekenhuizen
Hilversum, Postbus 10016, 1201 DA, Netherlands
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Postbus 1101, 5200 BD, Netherlands
Catharina ziekenhuis
Eindhoven, Postbus 1350, 5602 ZA, Netherlands
Vie Curie Medisch Centrum
Venlo, Postbus 1926, 5900 BX, Netherlands
Hagaziekhuis
The Hague, Postbus 40551, 2504 LN, Netherlands
Medisch Centrum Haaglanden
The Hague, Postbus 432, 2501 CK, Netherlands
Medisch Centrum alkmaar
Alkmaar, Postbus 50, 1800 AM, Netherlands
Maaslandziekenhuis
Sittard, Postbus 5500, 6130 MB, Netherlands
Tergooiziekenhuizen
Blaricum, Postbus 900, 1250 CA, Netherlands
Gelreziekenhuizen
Apeldoorn, Postbus 9014, 7300 DS, Netherlands
Amphia Ziekenhuis
Breda, Postbus 90157, 4800 RL, Netherlands
De Gelreziekenhuizen
Zutphen, Postbus 9020, 7200 GZ, Netherlands
Ziekenhuis Gelderse Vallei
Ede, Postbus 9025, 6710 HN, Netherlands
Elkerliek ziekenhuis
Helmond, Postbus 98, 5700 AB, Netherlands
Reinier de Graaf Groep
Delft, Netherlands
Deventer Ziekenhuis
Deventer, Netherlands
Slingeland Ziekenhuis
Doetinchem, Netherlands
St. Anna Ziekenhuis
Geldrop, Netherlands
Groene Hart Ziekenhuis
Gouda, Netherlands
Kennemer Gasthuis
Haarlem, Netherlands
Atrium Medisch Centrum
Heerlen, Netherlands
Westfriesgasthuis
Hoorn, Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Ziekenhuis Bernhoven
Oss, Netherlands
Laurentius Ziekenhuis
Roermond, Netherlands
Franciscus Ziekenhuis
Roosendaal, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
Maasstad Ziekenhuis
Rotterdam, Netherlands
Sint Franciscus Gasthuis
Rotterdam, Netherlands
Vlietland Ziekenhuis
Schiedam, Netherlands
Orbis Medisch Centrum
Sittard, Netherlands
't Lange Land Ziekenhuis
Zoetermeer, Netherlands
Related Publications (2)
van Nimwegen M, Speelman AD, Overeem S, van de Warrenburg BP, Smulders K, Dontje ML, Borm GF, Backx FJ, Bloem BR, Munneke M; ParkFit Study Group. Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. BMJ. 2013 Mar 1;346:f576. doi: 10.1136/bmj.f576.
PMID: 23457213DERIVEDvan Nimwegen M, Speelman AD, Smulders K, Overeem S, Borm GF, Backx FJ, Bloem BR, Munneke M; ParkFit Study Group. Design and baseline characteristics of the ParkFit study, a randomized controlled trial evaluating the effectiveness of a multifaceted behavioral program to increase physical activity in Parkinson patients. BMC Neurol. 2010 Aug 19;10:70. doi: 10.1186/1471-2377-10-70.
PMID: 20723221DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marten Munneke, Dr.
UMC st Radboud
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
September 5, 2008
First Posted
September 8, 2008
Study Start
September 1, 2008
Primary Completion
December 1, 2011
Study Completion
December 1, 2011
Last Updated
January 31, 2012
Record last verified: 2012-01